Neith Corporation (6236) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Neith Corporation TWD 2.43, price TWD 17.85, upside -86.4%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Neith Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range 8.12 TWD – 37.80 TWD · the 17.85 TWD price screens above the 2.43 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Neith in your weekly email
Every Wednesday you see whether Neith is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses. The company provides nutritional products, including L-One, a liquid formula for maintaining eye health; EPlus, a multiple enzyme supplement; and other nutritional products under the King One name. It also offers genetic testing services.
Show more
Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses. The company provides nutritional products, including L-One, a liquid formula for maintaining eye health; EPlus, a multiple enzyme supplement; and other nutritional products under the King One name. It also offers genetic testing services. In addition, the company offers energy and dual-purpose mattresses, energy masks, energy silicon gel necklaces, energy waistbands, energy heating stones, massage rods, and water purifiers, as well as Ganbanyoku, an energy stone spa bed. Further, it offers beauty care products, such as cell regeneration and rejuvenation series skin care products; home energy products; and microcontrollers and peripherals. Neith Corporation was formerly known as Come True Biomedical Inc. Neith Corporation was incorporated in 1997 and is based in Taichung, Taiwan.
Stock analysis
Neith Corporation (6236) currently trades at 17.85 TWD, while our model-based Fair Value estimate is 2.43 TWD, implying the stock looks roughly 634.8% overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 6.07 TWD per share, and 0 of the 18 models we run sit above the 17.85 TWD price.
Bear case: the Earnings-Based group reads lowest at 0.7500 TWD, and 18 of the 18 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Neith Corporation reported revenue of 36.1M TWD in FY2025 versus 31.4M TWD in FY2021, a compound +3.6%/yr. Reported net income was 3.2M TWD in FY2025.
Key figures
Market cap 744M TWD (≈ $23.4M) · P/S ratio 22.8 · EPS (TTM) 0.0100 TWD · Net margin 8.7% · Return on equity 0.2% · Return on assets (EBIT) −13.0% · Operating margin −9.7% · Revenue (TTM) 31.8M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −86%, 6236 screens richer than that median.
Fair Value models
Bear 2.43 TWDFair Value 2.43 TWDBull 2.43 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0074 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−20.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−29.3% (2021) → −2.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+33.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +31.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 647 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside−86.4% · Bottom 25%
Profitability
Return on equity (TTM)0.2% · Above median
Return on assets−0.8% · Above median
Net margin (TTM)1.0% · Below median
Operating margin (TTM)−9.7% · Bottom 25%
Growth and dividend
Revenue growth−2.3% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.15× · Cheapest 25%
P/S (TTM)0.74× · Cheapest 25%
P/FCF2.5× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)1· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Neith Corporation Fair Value". https://www.fairvalue-calculator.com/stock/6236
Frequently asked questions
Is Neith Corporation (6236) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 2.43 TWD versus a price of 17.85 TWD, about −86% upside (overvalued).
What is the fair value of 6236?
Our model-based fair value for Neith Corporation is 2.43 TWD (as of Sep 27, 2026), built from audited fundamentals. The current price: 17.85 TWD.
What is the quality score of 6236?
Neith Corporation has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neith Corporation (6236)?
Our model-based price target is the fair value of 2.43 TWD (as of Sep 27, 2026) from 18 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Neith Corporation stock forecast for 2026?
Our models put fair value at 2.43 TWD, about −86% upside versus a price of 17.85 TWD (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Neith Corporation (6236)?
Neith Corporation reported trailing-twelve-month revenue of about 31.8M TWD (latest available figure, as of Sep 27, 2026).
What growth is priced into Neith Corporation (6236)?
For today's price to be fair in a discounted-cash-flow model, Neith Corporation would have to grow free cash flow by +33.9 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +3.6 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 6236 use?
Our models discount Neith Corporation at 10.3 %: a base by market capitalisation (nano), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Neith Corporation that is +33.9 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Neith Corporation (6236) delivered so far?
Over the past 4 years revenue at Neith Corporation grew +3.6 % a year. The price currently implies +33.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Neith Corporation (6236) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Neith Corporation (+33.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Neith Corporation (6236)?
The free-cash-flow yield on the price is 1.25 %: that much free cash flow Neith Corporation produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Neith Corporation (6236)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neith Corporation it is 2.43 TWD per share (as of Sep 27, 2026), against a price of 17.85 TWD. It is the blended result of 18 valuation models (cash flow, earnings, asset, dividend).
Is Neith Corporation stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 6236 trades above its calculated fair value: price 17.85 TWD, fair value 2.43 TWD, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6236?
No. The price is what the market pays today (17.85 TWD); the fair value is what the company's own numbers justify (2.43 TWD). For Neith Corporation the two are 15.42 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Neith Corporation worth?
The market values Neith Corporation at about 744M TWD (market capitalisation, as of Sep 27, 2026). Per share that is 17.85 TWD; our models calculate a fair value of 2.43 TWD per share.
How solid is the balance sheet of Neith Corporation (6236)?
Balance-sheet figures for Neith Corporation (as of Sep 27, 2026): return on equity 0.2%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 6236 from its 52-week high?
Neith Corporation trades at 17.85 TWD, about 43% below its 52-week high of 31.10 TWD and 19% above the low of 14.95 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 2.43 TWD is for.
Which stocks are comparable to Neith Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neith Corporation stock attractive at the current price?
The data as of Sep 27, 2026: price 17.85 TWD, calculated fair value 2.43 TWD (−86%), Quality Score 74/100, from 18 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6236 calculated?
We run Neith Corporation through 18 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2.43 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Neith Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neith Corporation (6236)?
The closing price on Sep 24, 2026 was 17.85 TWD. Our model-based fair value is 2.43 TWD, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neith Corporation right now?
A high-quality business (quality 74/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (2.43 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Neith Corporation
How large is the market capitalisation of Neith Corporation (6236)?
The market capitalisation of Neith Corporation is 744M TWD (≈ $23.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neith Corporation (6236)?
The price-to-sales ratio of Neith Corporation is 22.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neith Corporation (6236)?
Earnings per share at Neith Corporation are 0.0100 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Neith Corporation (6236)?
The net margin of Neith Corporation is 8.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neith Corporation (6236)?
The return on equity (ROE) of Neith Corporation is 0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neith Corporation (6236)?
On an EBIT basis the return on assets of Neith Corporation is −13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neith Corporation (6236)?
The operating margin of Neith Corporation is −9.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neith Corporation (6236)?
Revenue at Neith Corporation is growing −2.3% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Neith Corporation (6236)?
Earnings per share at Neith Corporation are growing −96.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Neith Corporation in the live analysis
One click puts Neith Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
